John Byrd, MD, director of the Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, discusses the mechanism of acalabrutinib, a next-generation BTK inhibitor as a potential treatment for patients with chronic lymphocytic leukemia (CLL).

свернуть